Two men in suits chatting to a lady wearing a red jumper

Schizophrenia - Disease Management


A spotlight on psychiatry and movement disorders at the upcoming 2022 Psych Congress

The 35th Annual Psych Congress is returning to New Orleans on September 17–20 for four days of unparalleled comprehensive psychopharmacology education combined with state-of-the-art treatment approaches and emerging research findings. The unique, integrated forum allows all members of the mental health team to connect with the leading experts in psychiatry to help improve patient outcomes. This article highlights key activities on schizophrenia and tardive dyskinesia taking place at the congress.

Click here for more information on 2022 Psych Congress

Join the conversation!

Teva-sponsored symposia

Broadening Horizons: Artificial Intelligence and the Future of Digital Health in Psychiatry
Saturday 17 September | 7:30 – 8:30 PM CT | Hall D 
During this interactive session, Rakesh Jain, Daniel Guinart, and Eran Harary will discuss the unmet needs in mental health diagnosis and assessment, the growing field of digital psychiatry, and how artificial intelligence and machine learning may be used to optimize outcomes in psychiatry. 

Join the conversation on Twitter!

Breaking the Cycle of Social Disparities, Stigma, and Isolation in People with Neuropsychiatric Disorders
Sunday 18 September | 7:30 – 8:45 AM CT | Ballroom 252
In this symposium, Michael Compton, Cynthia Armand, and Craig Chepke will discuss why the social determinants of mental health are relevant to neuropsychiatric disorders, including schizophrenia and tardive dyskinesia. They will also discuss how clinicians can address the healthcare barriers faced by patients, and the psychiatric consequences of social determinants of mental health. 

Join the conversation on Twitter!

S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement – An Interactive Digital Platform to Educate on Schizophrenia Care
Monday 19 September | 2:00 – 3:00 PM CT | Hall D
Join John Kane, Jose Rubio, Christoph Correll, and Leslie Citrome for a stimulating discussion around the use of long-acting injectables in patients with schizophrenia, and an introduction to a new interactive digital platform to help educate clinicians on schizophrenia care.

Join the conversation on Twitter!

Teva Medical Affairs booth #417

The Teva Medical Affairs booth will feature a variety of educational resources and activities on schizophrenia and movement disorders. Visitors will be able to speak to members of the Teva team and pick up printed infographics on the background and burden of tardive dyskinesia, and the treatment of schizophrenia beyond clinical remission. Other booth highlights include videos on the anatomy of movement and motivational interviewing, an interactive globe showing what will be happening each day of the congress, kiosk screens linking to various assets, including CnsBytes, and the opportunity to explore the ‘clinical dilemmas’ section of the S.C.O.P.E.TM website.

Teva poster presentations*

Don’t miss these Teva-sponsored posters on tardive dyskinesia and schizophrenia, which will be available for viewing on Sunday 18 and Monday 19 September, 1:30 – 3:00 PM CT.

Tardive dyskinesia

  • Impact of Tardive Dyskinesia on Physical Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States
  • Impact of Tardive Dyskinesia on Psychological and Social Aspects of Patient Lives: A Survey of Patients and Caregivers in the United States
  • IMPACT-TD Registry: Real-World Assessment of the Impact and Progression of Tardive Dyskinesia
  • Tardive Dyskinesia: Epidemiological Trends in US Populations Based on Cross-Sectional Analysis of Retrospective Claims Data


  • Dispelling Myths and Misconceptions Surrounding the Use of Long-Acting Injectable Antipsychotic Agents for Treatment of Schizophrenia
  • Clinical Dilemmas in Schizophrenia Treatment and the Potential Place in Therapy of 
  • Long-Acting Antipsychotic Agents
  • Influence of Cultural Differences and Genetic Polymorphisms on Schizophrenia Management: An Exploratory Targeted Literature Review
  • Introducing S.C.O.P.E.™: Schizophrenia Clinical Outcome Scenarios and Patient-Provider Engagement – An Interactive Digital Platform to Educate on Schizophrenia Care
  • Understanding the Use of Long-Acting Injectable Antipsychotic Agents in Schizophrenia: A 2022 Survey of US Psychiatrists, Nurse Practitioners, and Physician Associates

Sessions of interest to look out for* 

Saturday 17 September – Psychopharmacology sessions

  • The Muscarinic Cholinergic System’s Role in Schizophrenia: Pathophysiology and Emerging Treatments | 8:30 – 9:45 AM CT | Hall E2. Craig Chepke and Jonathan M. Meyer
  • Addressing Persistent Myths and Misconceptions in Tardive Dyskinesia | 11:30 AM –12:45 PM CT | Hall E2. Craig Chepke, Kevin N. Williams, and Bethany Yeiser
  • Long-Acting Injectable Antipsychotics: Newer Strategies for the Optimal Management of Bipolar Disorder I | 4:00 – 5:15 PM CT | Hall E2. Christoph U. Correll, Veronica Ridpath, and Vanessa Joy Walker

Saturday 17 September – Innovation Theater Lunch (Industry Sponsored)

  • TAAR1: Science Behind a Potential New TAARget for Schizophrenia | 1:00 – 2:15 PM CT | Room 252. Craig Chepke and Vladimir Maletic (Sunovion Pharmaceuticals Inc. and Otsuka America Pharmaceutical, Inc.)
  • Tardive Dyskinesia: Overcoming the Challenges of Differential Diagnosis & Treatment in the Era of Telepsychiatry | 1:00 – 2:15 PM CT | Room 265 - 268. Jonathan M. Meyer and Jo A. Hughes (Neurocrine Biosciences, Inc.)

Sunday 18 September – Innovation Theater Lunch (Industry Sponsored)

  • Are you Talking with your Adult Patients Living with Bipolar Disorder About Maintenance Treatment with a Long-Acting Injectable (LAI)? | 12:00 – 1:15 PM CT | Room 356. Gustavo Alva and Erin C. Crown (Otsuka America Pharmaceutical, Inc. and Lundbeck.)
  • Utilizing the AIMS in Assessing for Tardive Dyskinesia | 12:00 – 1:15 PM CT | Room 255. Roger McIntyre (Neurocrine Biosciences, Inc.)

Monday 19 September

  • Telehealth as Part of the Treatment Plan for Adults with Schizophrenia on LAIs | 7:30 – 8:45 AM CT | Room 255. Leslie Citrome, Andrew J. Cutler, and Jonathan M. Meyer (Innovation Theater Breakfast; Janssen Pharmaceuticals, Inc)
  • Breaking Down the Barriers to Utilizing LAI APs for Schizophrenia Management | 9:00 – 10:15 AM CT | Hall E2. Jonathan M. Meyer and Desiree Matthews (Psychopharmacology session)
  • State of Schizophrenia | 10:30 – 11:45 AM CT | Hall E1. Christoph U. Correll (Psychotic disorders session)
  • Making a Difference for Patients with Tardive Dyskinesia Proactively Recognizing and Treating an Overlooked Disorder | 12:00 – 1:15 PM CT | Room 252. Richard Jackson (Innovation Theater Lunch)

Tuesday 20 September – Innovation Theatre Lunch (Industry sponsored)

  • Rethink Treatment for Adults with Schizophrenia or Bipolar I Disorder | 12:00 – 1:15 PM CT | La Nouvelle. Roueen Rafeyan (Janssen Pharmaceuticals, Inc)

*Posters and sessions that mention drug names have been excluded from this article.